Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

Meeks, Joshua J., Bellmunt, Joaquim, Bochner, Bernard H., Clarke, Noel W., Daneshmand, Siamak, Galsky, Matthew D., Hahn, Noah M., Lerner, Seth P., Mason, Malcolm David, Powles, Thomas, Sternberg, Cora N. and Sonpavde, Guru 2012. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. European Urology 62 (3) , pp. 523-533. 10.1016/j.eururo.2012.05.048

Full text not available from this repository.

Abstract

Context Muscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC. Objective To review the data supporting perioperative chemotherapy and emerging regimens for MIBC. Evidence acquisition Medline databases were searched for original articles published before April 1, 2012, with the search terms bladder cancer, urothelial cancer, radical cystectomy, neoadjuvant chemotherapy, and adjuvant chemotherapy. Proceedings from the last 5 yr of major conferences were also searched. Novel and promising drugs that have reached clinical trial evaluation were included. Evidence synthesis The major findings are addressed in an evidence-based fashion. Prospective trials and important preclinical data were analyzed. Conclusions Cisplatin-based neoadjuvant combination chemotherapy is an established standard, improving overall survival in MIBC. Pathologic complete response appears to be an intermediate surrogate for survival, but this finding requires further validation. Definitive data to support adjuvant chemotherapy do not exist, and there are no data to support perioperative therapy in cisplatin-ineligible patients. Utilization of neoadjuvant cisplatin is low, attributable in part to patient/physician choice and the advanced age of patients, who often have multiple comorbidities including renal and/or cardiac dysfunction. Trials are using the neoadjuvant paradigm to detect incremental pathologic response to chemobiologic regimens and brief neoadjuvant single-agent therapy to screen for the biologic activity of agents.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: bladder cancer, urothelial cancer, muscle invasive, radical cystectomy, neoadjuvant therapy, adjuvant therapy
Publisher: Elsevier
ISSN: 0302-2838
Last Modified: 04 Jun 2017 04:33
URI: http://orca-mwe.cf.ac.uk/id/eprint/40941

Citation Data

Cited 82 times in Google Scholar. View in Google Scholar

Cited 122 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item